“I am an advocate for psychedelics. I can’t help it,” explains 57-year-old Jacqueline Lopez, “I mean, it wasn’t that long ago that I thought to myself, ‘What are you thinking, Jackie? These are Schedule I drugs. You can’t just go around talking about them.’ But the science behind it is superb and I had seen…
The psychedelics industry is similar to where the cannabis industry was 10 years ago as it fights for legalization in various countries. Retail establishments in the Netherlands that specializes in the sale of psychoactive substances, such as magic truffles, are called Smart Shops. There are an estimated 100 Smart Shops operating in the Netherlands, generating…
Even the Department of Veterans Affairs (VA) has started offering psychedelic substances to patients as a part of clinical trials. Veteran Luke Gruber said, “I didn’t want the pills provided by the Department of Veterans Affairs. And talk therapy just didn’t help. Rudderless and prone to extreme mood swings, I increasingly isolated myself from family…
The veteran patients will receive low-dose, multi-dose psilocybin for oral use… …which received Good Manufacturing Practice certification, and will be given to patients in a labeled package with at-home instructions. Original Article (High Times):North America’s first take home psilocybin trial approved in CanadaArtwork Fair Use: Konoimagination
…with so many cities and counties voting on the issue in November [2022], it could lead to bans across large portions of the state. …psilocybin has become hotly-contested across the state. Some counties that voted for it in 2020 are now voting on it again, like Clackamas, Tillamook and Deschutes. It’s not on the ballot…
Robin Feldman, an expert on pharmaceutical intellectual property at the University of California Hastings College of Law… …said the conflict over psychedelics reflects the larger problems of a patent system that saddles Americans with some of the highest prescription drug prices in the world. “It’s not pretty when you look under the hood,” she said.…
The competition for patents is well under way… each company has interpreted the decision as a win, with Freedom to Operate saying the decision limits Compass Pathways’ “ownership [to] . . . the exact shape of their form of psilocybin, and not others,” while Compass Pathways does not “see how avoiding infringing on their patents…
As part of their efforts to better understand DEA’s administrative process, Aggarwal [Washington State, Seattle] and his counsel have submitted several Freedom of Information Act (FOIA) requests for relevant documents. DEA’s FOIA policy states that it will consider waiving or reducing fees if the requester is shows that the information is “in the public interest because…
Published in the Journal, Drug Science, Policy and Law, [with authors Rayyan Zafar and David Nutt (who performed the first MRI of a human brain under the influence of LSD)], from Imperial College London, Centre for Psychedelic Research and Neuropsychopharmacology, UK: this case highlights the plausible therapeutic role of such plant-based medicines in oncology treatment…
More than 40 researchers now work at the center on studies looking at the effects of psilocybin on anorexia, smoking, major depressive disease, Alzheimer’s disease, and other conditions… …patients are already clamoring for the treatment, which for many brings dramatic results in just a few sessions… “cautiously optimistic” that the Food and Drug Administration and…
Recent Comments